Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PMCB

PharmaCyte Biotech Inc

Nov 04 • 04:00PM ET

0.8900

-0.0274 -2.99 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB INCY BMRN NBIX EXEL LGND

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	10.38%	Shs Outstand	6.80M	Perf Week	-9.46%
Market Cap	6.05M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.09M	Perf Month	-13.59%
Enterprise Value	-7.39M	PEG	-	EPS next Q	-	Inst Own	8.49%	Short Float	7.89%	Perf Quarter	4.71%
Income	-3.52M	P/S	-	EPS this Y	-	Inst Trans	0.12%	Short Ratio	4.71	Perf Half Y	-20.54%
Sales	0.00M	P/B	0.14	EPS next Y	-	ROA	-1.95%	Short Interest	0.48M	Perf YTD	-43.31%
Book/sh	6.41	P/C	0.45	EPS next 5Y	-	ROE	-2.33%	52W High	1.94 -54.12%	Perf Year	-50.83%
Cash/sh	1.98	P/FCF	-	EPS past 3/5Y	- -	ROIC	-8.07%	52W Low	0.80 11.25%	Perf 3Y	-70.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.23% 4.95%	Perf 5Y	-93.59%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-168.03%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-99.42%
Dividend Ex-Date	-	Quick Ratio	18.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.56	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	18.01	EPS Q/Q	-164.70%	SMA20	-8.60%	Beta	0.06	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-9.75%	Rel Volume	0.34	Prev Close	0.92
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	-24.95%	Avg Volume	102.08K	Price	0.89
IPO	Sep 11, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	34,792	Change	-2.99%

Sep-02-25 09:20AM	PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications (Business Wire)
Aug-20-25 09:15AM	PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing (Business Wire) -7.22%
Aug-18-25 09:15AM	PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors (Business Wire) +12.23%
May-21-24 09:00AM	PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease (Business Wire)
Mar-19-24 06:53AM	PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024 (InvestorPlace) +6.47%
11:51AM	Loading…
Dec-18-23 11:51AM	PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 (InvestorPlace)
Nov-15-23 08:30AM	PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. (Business Wire)
07:30AM	Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech (GlobeNewswire)
Oct-31-23 09:15AM	PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology (Business Wire)
Jun-15-23 09:15AM	PharmaCyte Biotech Announces Final Results of Tender Offer (Business Wire)
May-11-23 08:30AM	PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share (Business Wire) +12.77%
Feb-02-23 09:00AM	PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan (Business Wire)
Oct-07-22 09:00AM	PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value (GlobeNewswire)
Aug-15-22 08:30AM	PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital (Business Wire)
Jul-28-22 12:49PM	PharmaCyte Biotech Rebukes Iroquois Commencement of Consent Solicitation (Business Wire)
09:00AM	Loading…
09:00AM	Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc. (PR Newswire)
Jul-21-22 08:30AM	PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study (Business Wire)
Jul-19-22 08:30AM	PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study (Business Wire)
Jul-11-22 08:30AM	PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 (Business Wire)
06:00AM	IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS (PR Newswire)
Jul-05-22 03:16PM	IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS (PR Newswire)
08:30AM	PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells (Business Wire)
Jun-23-22 09:00AM	IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING (PR Newswire)
Jun-15-22 08:30AM	PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capitals Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value (Business Wire)
Jun-13-22 08:30AM	PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego (Business Wire)
Jun-09-22 09:00AM	IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS (PR Newswire)
Jun-08-22 08:30AM	PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value (Business Wire)
Jun-02-22 09:00AM	PharmaCyte Biotech to Implement $10-Million Share Repurchase Program (Business Wire)
May-23-22 09:00AM	PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites (Business Wire)
May-11-22 09:00AM	Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors (PR Newswire)
09:00AM	Loading…
Apr-27-22 09:00AM	PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes (Business Wire)
Apr-19-22 09:00AM	PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements (Business Wire) -8.18%
Apr-13-22 09:00AM	PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial (Business Wire)
Apr-05-22 09:00AM	PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors (Business Wire)
Mar-22-22 09:00AM	PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate (Business Wire)
Mar-16-22 09:00AM	PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights (Business Wire)
Feb-22-22 09:00AM	PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration (Business Wire)
Feb-14-22 09:00AM	PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA (Business Wire)
Jan-06-22 09:00AM	PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference (Business Wire)
Jan-04-22 09:00AM	PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells (Business Wire)
Dec-28-21 09:00AM	PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study (Business Wire)
Dec-15-21 09:00AM	PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights (Business Wire) +6.67%
Dec-08-21 10:16AM	PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay (Business Wire)
Nov-30-21 01:05AM	PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study (Business Wire)
Nov-12-21 09:00AM	PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation (Business Wire)
Sep-27-21 09:00AM	PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA (Business Wire)
Sep-21-21 09:00AM	PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests (Business Wire) +5.79%
Sep-16-21 09:00AM	PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA (Business Wire)
Sep-08-21 09:00AM	PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire) +5.56%
Aug-31-21 09:20AM	PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study (Business Wire)
Aug-25-21 09:00AM	PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise (Business Wire)
Aug-23-21 04:39PM	PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules (Business Wire) +5.17%
Aug-19-21 07:19AM	PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Business Wire) -64.85%
Aug-16-21 09:00AM	PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus (Business Wire) -9.48%
Aug-12-21 03:00PM	PharmaCyte Biotech Announces Closing of $15-Million Public Offering (Business Wire) -20.28%
Aug-09-21 05:37PM	PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering (Business Wire) -22.22% -56.71%
Aug-02-21 04:58PM	PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering (Business Wire) -8.41% -14.09%
Jul-14-21 08:45AM	PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq (Business Wire) +27.54%
Jul-13-21 07:57PM	PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank (Business Wire) -21.43%
Jul-09-21 07:11PM	PharmaCyte Biotech Announces Reverse Stock Split (Business Wire) -41.73%
Jul-08-21 09:00AM	PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders (Business Wire)
Jun-24-21 09:00AM	PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold (Business Wire) +10.42%
Jun-22-21 09:00AM	PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital (Business Wire) +14.67%
Jun-18-21 09:00AM	PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available (Business Wire) -20.69%
Jun-14-21 09:00AM	PharmaCyte Biotech Announces Details to Attend This Weeks Virtual Annual Meeting of Shareholders (Business Wire)
Apr-01-21 09:00AM	PharmaCyte Biotech Successfully Completes 1 Year Stability Study (Business Wire) +15.20%

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMCB

PharmaCyte Biotech Inc

Upgrade your FINVIZ experience